Royal Philips, the Netherlands-based health company, has received 510(k) clearance from the US Food and Drug Administration (FDA) for its AlluraClarity interventional X-ray system, which provides quality imaging for a range of clinical procedures.
Equipped with its ClarityIQ technology, the system offers quality imaging and greater visibility, even at low X-ray dose levels.
Philips claimed that the system’s low X-ray dose settings will aid clinicians in managing exposure to radiation.
ClarityIQ technology is available as an upgrade on a majority of Philips’ monoplane and biplane interventional X-ray systems, serving as a cost-effective solution for hospitals.
Philips Healthcare Imaging Systems CEO Gene Saragnese said the transition from highly invasive surgical procedures to minimally-invasive image-guided therapies, with all their intrinsic patient benefits, is a transformation in the delivery of healthcare that is rapidly accelerating globally.
"AlluraClarity is a perfect example of how Philips’ close collaboration with clinical partners has combined these two areas of innovation to facilitate more advanced treatment while at the same time managing radiation dose," Saragnese added.
The Netherlands-located St. Antonius Hospital interventional radiologist Dr. Marco van Strijen said the hospital has been using AlluraClarity system for more than a year now and have grown to appreciate the low dose settings.
"All patients treated via X-ray guided interventions benefit from the advantage of low radiation exposure, but it is especially important when you are treating patients who have to undergo lengthy and complex procedures," Strijen added.
Prior to the US FDA approval, the AlluraClarity system has been commercially available outside the US since 2012 and more than 200 systems have been sold so far.
Philips’ investment in healthcare research and development totalled €803m in 2012.
Image: Philips AlluraClarity interventional X-ray system. Photo courtesy of PRNewsWire /Royal Philips.